Literature DB >> 23041403

Cerebrospinal fluid IL-21 levels in Neuromyelitis Optica and multiple sclerosis.

Aimin Wu1, Xiaonan Zhong, Honghao Wang, Wen Xu, Chen Cheng, Yongqiang Dai, Jian Bao, Wei Qiu, Zhengqi Lu, Xueqiang Hu.   

Abstract

BACKGROUND: Neuromyelitis optica (NMO) and multiple sclerosis (MS) are inflammatory demyelinating diseases of human central nervous system (CNS) with complex pathogenesis. IL-21/IL-21R regulates activation, proliferation and survival of both T cells and B cells, which are involved in the pathogenesis of NMO and MS. High levels of serum IL-21 were observed in NMO patients. However, concentration of cerebrospinal fluid (CSF) IL-21 in MS and NMO patients still remain unknown. OBJECT: To detect the CSF concentration of IL-21 in NMO and MS patients and to evaluate its relationship with disease activity, particularly concerned about its impact on humoral immunity.
METHODS: CSF IL-21 was detected by an enzyme-linked immunosorbent assay (ELISA) in NMO patients (n=21), MS patients (n=20) and controls (n=16).
RESULTS: CSF concentration of the IL-21 was noticeably elevated in NMO (p=0.012) and borderline significantly increased in MS (p=0.115). In addition, this occurrence was associated with humoral immune activity as shown by a correlation between IL-21 and complement in NMO cohort (p=0.023) and high IL-21 levels in autoantibody-positive subgroup (p=0.027).
CONCLUSIONS: The concentration of CSF IL-21 was noticeably elevated and might have a positive correlation with humoral immune activity in NMO.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23041403     DOI: 10.1017/s0317167100015663

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  8 in total

1.  Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase.

Authors:  P O Barros; T Cassano; J Hygino; T B Ferreira; N Centurião; T M Kasahara; R M Andrade; U C Linhares; A F B Andrade; C C F Vasconcelos; R Alvarenga; R Marignier; C A M Bento
Journal:  Clin Exp Immunol       Date:  2015-12-01       Impact factor: 4.330

Review 2.  B cells in MS and NMO: pathogenesis and therapy.

Authors:  Markus Krumbholz; Edgar Meinl
Journal:  Semin Immunopathol       Date:  2014-05-16       Impact factor: 9.623

3.  Immune Parameters That Distinguish Multiple Sclerosis Patients from Patients with Other Neurological Disorders at Presentation.

Authors:  Athanasia Mouzaki; Maria Rodi; Nikolaos Dimisianos; Andreas Emmanuil; Dimitra Kalavrizioti; Rosa Lagoudaki; Nikolaos C Grigoriadis; Panagiotis Papathanasopoulos
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

4.  IL-21 optimizes T cell and humoral responses in the central nervous system during viral encephalitis.

Authors:  Timothy W Phares; Krista D DiSano; David R Hinton; Mihyun Hwang; Allan J Zajac; Stephen A Stohlman; Cornelia C Bergmann
Journal:  J Neuroimmunol       Date:  2013-08-06       Impact factor: 3.478

5.  Circulating Memory T Follicular Helper Cells in Patients with Neuromyelitis Optica/Neuromyelitis Optica Spectrum Disorders.

Authors:  Xueli Fan; Yanfang Jiang; Jinming Han; Jingyao Liu; Yafen Wei; Xinmei Jiang; Tao Jin
Journal:  Mediators Inflamm       Date:  2016-03-09       Impact factor: 4.711

Review 6.  Advances in Biomarker-Guided Therapy for Pediatric- and Adult-Onset Neuroinflammatory Disorders: Targeting Chemokines/Cytokines.

Authors:  Michael R Pranzatelli
Journal:  Front Immunol       Date:  2018-04-04       Impact factor: 7.561

7.  Open-label, add-on trial of cetirizine for neuromyelitis optica.

Authors:  Ilana Katz Sand; Michelle T Fabian; Russell Telford; Thomas A Kraus; Mirna Chehade; Madhan Masilamani; Thomas Moran; Colleen Farrell; Shelly Ebel; Lawrence J Cook; John Rose; Fred D Lublin
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2018-02-02

Review 8.  A Comprehensive Review on the Role of Genetic Factors in Neuromyelitis Optica Spectrum Disorder.

Authors:  Soudeh Ghafouri-Fard; Tahereh Azimi; Mohammad Taheri
Journal:  Front Immunol       Date:  2021-10-05       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.